Viral Antigen Protein Production for Research Reagents Using CFPS

Cell-free protein synthesis (CFPS) makes viral antigen production for research reagents more tractable by separating protein synthesis from the need to sustain a living host. Its main advantage is that researchers can control the reaction environment directly, which helps them deal with cytotoxicity, insolubility, and slow construct testing. For most research-scale antigen workflows, that makes CFPS a practical starting point and, increasingly, a sufficient production platform.

Why viral antigen production for research reagents is genuinely hard

SARS-CoV-2 exposed the difficulty of obtaining soluble N, M, E, and spike antigens quickly and at low cost. At the start of a pandemic, the conventional expression pipeline was too slow for the demand. Yet speed was not the only obstacle, because these targets included membrane-associated and nucleocapsid proteins that are difficult to express in useful form. Producing protein was therefore only part of the task. The material also had to be soluble and suitable for downstream research and diagnostic development.

Viral proteins that disrupt membranes, hijack cellular machinery, or trigger apoptosis can kill cells before useful yields accumulate. Meanwhile, cloning, transformation, colony selection, and culture amplification make each construct test a process measured in days to weeks. Insolubility adds to that delay when an expressed construct still yields no usable antigen. Even successful production leaves a standardization problem, because lot-to-lot differences in reagents can propagate into assay variability.

What CFPS actually does mechanistically and why it sidesteps these problems

CFPS removes the living host from the synthesis step while retaining the machinery needed to make protein. It uses mRNA or DNA templates, including linear PCR products and circular plasmids, with transcription and translation machinery extracted from cells. With no living cells to keep alive during synthesis, expression of a cytotoxic target is free of the limits set by host survival. This removes a central biological constraint rather than merely improving the host’s tolerance. It does not, however, make folding automatic or make every extract suitable for every antigen.

Researchers can adjust pH, temperature, redox potential, and substrate concentrations in real time rather than working through the constraints of a living cell. Cofactors, chaperones, and disulfide-bond-forming enzymes can also be added directly. These additions allow the environment to support structurally complex proteins without requiring a viable host to accommodate the same conditions.

E. coli extracts offer the highest protein yields, lowest cost, and least batch-to-batch variation, making them the practical default for most viral antigen work. Wheat germ extracts support eukaryotic proteins requiring near-native folding, while rabbit reticulocyte and Pichia pastoris-based systems provide other eukaryotic contexts. These options serve different structural requirements.

Validated viral antigen targets: what CFPS has actually expressed

Lin Wang and colleagues expressed the SARS-CoV-2 nucleocapsid, membrane, and envelope proteins using an E. coli-based CFPS system. Their work optimized solubility with amphipathic molecules and removed most impurities through one-step Ni-NTA affinity chromatography. For the nucleocapsid protein, the coding sequence was codon-optimized for CFPS translation, and Western blot showed a distinct band at the expected molecular weight of 49 kDa. This is concrete evidence of expression of a difficult viral target. The molecular-weight result alone cannot show that a finished antigen reagent has every property it needs.

The SARS-CoV-2 spike example demonstrates a related but distinct use of the platform. An accelerated cell-free workflow supported antibody discovery against spike using synthetically dimerized antigen-binding fragments. It combined high-throughput linear DNA assembly with E. coli CFPS optimized for disulfide bond formation. That result supports CFPS as a tool for antigen-directed discovery, rather than establishing production of every spike antigen format.

A Pichia pastoris-based CFPS system produced hepatitis B core antigen VLPs with characteristics comparable to those produced in vivo, together with a synthesis, assembly, and purification methodology for rapid prototyping. E. coli-based CFPS also generated rAAV5 VP3 protein that was mostly soluble and spontaneously formed capsid particles. Beyond virology, CFPS with nanolipoproteins produced the major outer membrane protein (mMOMP) of Chlamydia spp. in native trimeric form. Various cell extracts have also made proteins with up to 24 disulfide bonds, which shows that they can handle substantial structural complexity, though viral surface proteins may differ in how they behave.

Speed and iteration: how CFPS compresses the antigen development cycle

CFPS changes the calendar because synthesis can begin directly from PCR products or plasmid templates. Linear-template workflows do not require cloning into expression vectors, transformation, colony selection, or culture amplification before the expression test. Depending on the system, batch synthesis finishes within roughly one and a half to three hours. A full expression-to-functional-assay cycle can therefore take one to two days, compared with one to two weeks through live-cell workflows. The relevant gain is not just faster synthesis, but earlier access to the result that determines the next experiment.

Different truncations, domain boundaries, fusion tags, and sequence variants can be tested in parallel within a single working day. Extract-based CFPS systems can efficiently express 24 open reading frames in a single day, so researchers can work with a panel of constructs at a time. Failed constructs can then be discarded before investment in cell line development or scale-up. For applications driven by rapid discovery, this makes CFPS a better fit for the required pace rather than a universal replacement for cellular expression.

High-throughput screening of antigen variants in plate-based CFPS workflows

Plate-based CFPS turns rapid expression into a parallel screening workflow. Automated setups support a single construct through to 96 unique reactions in standard plate formats, allowing antigen sequence variants and expression conditions to be compared within the same experimental round. With small reaction volumes, the reagents for each variant cost less. Standard incubators and liquid-handling equipment are sufficient, without specialized bioreactor infrastructure. This format suits work aimed at mapping epitopes, identifying stabilizing mutations, or optimizing expression constructs.

A 2026 study in FEBS Open Bio found that activity rankings for staphylokinase variants in crude CFPS mixtures closely matched rankings from purified proteins, as assessed through chromogenic activity assays. Baker & Mulvihill described a single-plate expression and assay protocol in Current Protocols in 2025 that provided sufficient purity and yield for direct plate-based enzymatic assays. These results support screening without additional purification where the readout permits it. They do not establish that every viral antigen binding assay will tolerate crude reaction mixtures.

For compatible assays, removing purification prevents that step from multiplying across every variant in every screening round. The open reaction also allows non-natural substrates, toxic conditions, or non-canonical amino acids that are incompatible with living cells. Documented formulations are equally important, because they allow researchers to understand and troubleshoot the conditions behind each result.

Milligram-scale antigen production from the same CFPS platform

A productive screening platform must also supply enough selected antigen for downstream work. The same CFPS platform can produce milligram quantities for binding assays, immunization, and diagnostic reagent production without requiring a change of expression system. E. coli-based batch reactions yield roughly 100 µg/mL to two to three mg/mL, depending on the protein and conditions. The Chlamydia spp. mMOMP work reached around 1.5 mg/mL, placing a demanding multimeric antigen within a directly useful research-scale range.

A formulation using potassium glutamate, nucleotide monophosphates, amino acids, and E. coli extract enabled protein production at $133 per liter. That formulation figure should be distinguished from the cost of a purified, application-ready antigen. Da Silva, Matthews et al. reported in their medRxiv 2025 multi-site implementation study that CFPS-related antigen production cost reached a fraction of a dollar per mouse dose before purification. Together, the yield and cost examples show that CFPS can extend beyond construct discovery into usable reagent production.

Reproducibility and reagent transparency as prerequisites for antigen standardization

Quantity and cost are only useful if antigen performance remains consistent. There have been concerns about reproducibility and low yields in cell-free systems, and about how fully they can carry out post-translational modifications. The undefined composition of crude lysates is a root cause of the difficulty, because researchers cannot systematically diagnose variation in components they cannot audit. Total-protein quantification can also count inactive species. A reported concentration can then misrepresent the amount of active material available to a downstream assay.

Olsen, Copeland, Jewett et al. published a design-driven optimization of reagent formulations in Nature Communications in March 2026 that addressed both cost and robustness. The formulations reduced cost relative to previous cell-free reagents and performed robustly across batches of cell lysates, multiple users, and multiple locations. The work covered fifteen therapeutically relevant products, including full-length aglycosylated monoclonal antibodies. Its significance for antigen standardization is the demonstration of performance beyond a single optimized laboratory, rather than proof that every antigen is already standardized. Da Silva et al. also reported in medRxiv 2025 that research teams in North America, South America, and Asia had put the same CFPS-based approach to making antigen into use locally.

Those findings show why transparency is needed for the work itself as well as for decisions about what to buy. Documented formulations allow researchers to diagnose failures, adjust conditions deliberately, and reproduce work across laboratories. Lot-level QC data provides the corresponding evidence for judging whether a particular batch is fit for an application before critical samples are committed. Neither documentation nor a yield figure substitutes for relevant activity measurements. Together, however, formulation transparency and lot-level characterization provide a defensible basis for antigen standardization.

Where cell-based expression still makes sense and how to choose

CFPS is the stronger starting point when an antigen is toxic, membrane-associated, or needed quickly in small-to-milligram quantities for assay development. It also works well for rapid construct screening, early tests of feasibility, and proteins that need non-canonical amino acids or redox environments that can be precisely controlled. Its direct-template workflow is particularly useful where cloning and transformation infrastructure are limited or turnaround time is critical. These advantages follow from the same mechanism, which is removal of the living host as a constraint. The choice should still depend on the antigen form needed as well as speed.

E. coli-based CFPS does not produce glycoproteins, and many eukaryotic cell-free systems require supplementation for complex post-translational modifications. Some glycan patterns are therefore better served by mammalian or insect cell expression, particularly when glycan-dependent epitopes determine antigen function. Cell-based expression is also a good choice when secretory pathway processing needs intact ER and Golgi machinery. Where those properties are essential, soluble expression alone is not an adequate basis for choosing the platform.

A hybrid strategy preserves the speed of CFPS without ignoring those boundaries. CFPS can identify the best-expressing construct and confirm functionality before a transition to cell-based expression if scale or glycosylation requirements demand it. If CFPS already yields enough of the selected antigen with the required structure and function, researchers can keep using it. For most researchers producing viral antigens for research reagents, CFPS is where the work starts, and increasingly where it finishes.